Literature DB >> 6705426

Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

K M Giacomini, T F Blaschke.   

Abstract

Disopyramide exhibits concentration-dependent binding to plasma proteins at therapeutic plasma concentrations. This paper reviews the effect of this type of binding on both the pharmacokinetic and pharmacodynamic properties of the drug. For a drug with capacity-limited, binding-sensitive elimination like disopyramide, concentration-dependent binding to plasma proteins produces a non-linear relationship between dosing rate and total plasma concentrations of the drug. However, when dosing rate is related to unbound concentrations of drug, the relationship is linear. Renal clearance of total disopyramide has been found to depend on the unbound fraction whereas renal clearance of unbound drug may be dependent upon time after drug administration as well as route of drug administration. However, due to some potential methodological problems, these data need verification. The concentration-dependent binding of disopyramide to plasma proteins, with its resultant effects on clearance and distribution, produces a concave curvature in the log unbound concentration versus time curves and a log-linear decline in total plasma concentration versus time after intravenous administration of the drug. Several pharmacological studies suggest that the unbound drug is active in terms of producing both desirable and undesirable effects. Hence, monitoring unbound concentrations of disopyramide seems more rational for clinical purposes. The few studies that have been carried out examining the optical isomers of disopyramide have suggested that both the pharmacokinetic and pharmacodynamic properties of the drug are stereoselective. Recent data reveal stereoselective binding to plasma proteins in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705426     DOI: 10.2165/00003088-198400091-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  23 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.

Authors:  J W Ward; G R Kinghorn
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

5.  Disopyramide binding to serum protein in man and animals.

Authors:  J J Lima; D B Haughey
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

6.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

7.  The renal clearance of disopyramide after bolus intravenous injection.

Authors:  J R Lawrence; S M Bryson; D J Sumner; B C Campbell; B Whiting
Journal:  Biopharm Drug Dispos       Date:  1979 Oct-Dec       Impact factor: 1.627

8.  The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study.

Authors:  C Pollick; K M Giacomini; T F Blaschke; W L Nelson; K Turner-Tamiyasu; V Briskin; R L Popp
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

9.  Calculation of drug concentration in plasma after equilibrium dialysis.

Authors:  K M Giacomini; A Abang; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

10.  Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.

Authors:  W L Nelson; C K Sneed; K M Giacomini; J C Giacomini; J Stauss; T F Blaschke; B M Cox
Journal:  J Med Chem       Date:  1981-05       Impact factor: 7.446

View more
  6 in total

1.  Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide.

Authors:  D Rousson; C Piolat; J Galleyrand; S Ferry; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.

Authors:  J Longmore; J L Berry; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 5.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

6.  In Vitro Bioavailability of the Hydrocarbon Fractions of Dimethyl Sulfoxide Extracts of Petroleum Substances.

Authors:  Yu-Syuan Luo; Kyle C Ferguson; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.